Bifunctional Nitrone-Conjugated Secondary Metabolite Targeting the Ribosome

Limbrick, Emilianne M.; Graf, Michael; Derewacz, Dagmara K.; Nguyen, Fabian; Spraggins, Jeffrey M.; Wieland, Maximiliane; Ynigez-Gutierrez, Audrey E.; Reisman, Benjamin J.; Zinshteyn, Boris; McCulloch, Kathryn M.; Iverson, T. M.; Green, Rachel; Wilson, Daniel N. and Bachmann, Brian O. (2020): Bifunctional Nitrone-Conjugated Secondary Metabolite Targeting the Ribosome. In: Journal of the American Chemical Society, Vol. 142, No. 43: pp. 18369-18377

Abstract

Many microorganisms possess the capacity for producing multiple antibiotic secondary metabolites. In a few notable cases, combinations of secondary metabolites produced by the same organism are used in important combination therapies for treatment of drug-resistant bacterial infections. However, examples of conjoined roles of bioactive metabolites produced by the same organism remain uncommon. During our genetic functional analysis of oxidase-encoding genes in the everninomicin producer Micromonospora carbonacea var. aurantiaca, we discovered previously uncharacterized antibiotics everninomicin N and O, comprised of an everninomicin fragment conjugated to the macrolide rosamicin via a rare nitrone moiety. These metabolites were determined to be hydrolysis products of everninomicin P, a nitrone-linked conjugate likely the result of nonenzymatic condensation of the rosamicin aldehyde and the octasaccharide everninomicin F, possessing a hydroxylamino sugar moiety. Rosamicin binds the erythromycin macrolide binding site approximately 60 angstrom from the orthosomycin binding site of everninomicins. However, while individual ribosomal binding sites for each functional half of everninomicin P are too distant for bidentate binding, ligand displacement studies demonstrated that everninomicin P competes with rosamicin for ribosomal binding. Chemical protection studies and structural analysis of everninomicin P revealed that everninomicin P occupies both the macrolide- and orthosomycin-binding sites on the 70S ribosome. Moreover, resistance mutations within each binding site were overcome by the inhibition of the opposite functional antibiotic moiety binding site. These data together demonstrate a strategy for coupling orthogonal antibiotic pharmacophores, a surprising tolerance for substantial covalent modification of each antibiotic, and a potential beneficial strategy to combat antibiotic resistance.

• Item Type: Journal article
• Faculties: Chemistry and Pharmacy > Department of Biochemistry
• Subjects: 500 Science > 540 Chemistry
• ISSN: 0002-7863
• Language: English